利妥昔单抗(Rituximab) - 药物靶点：CD20_在研适应症：心脏移植排斥反应，肝移植排斥反应，肺移植排斥反应_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

IDEC-C2B8-anti-CD20、Ristova、Rituximab (Genetical Recombination)

+ [14]

靶点

CD20

作用方式

抑制剂

作用机制

CD20抑制剂(B淋巴细胞抗原CD20抑制剂)、ADCC(抗体依赖的细胞毒作用)、CD20定向的溶细胞作用

治疗领域

肿瘤免疫系统疾病感染+ [11]

在研适应症

心脏移植排斥反应肝移植排斥反应肺移植排斥反应+ [140]

非在研适应症

急性双系白血病急性移植物抗宿主病成人急性髓性白血病+ [145]

原研机构

Genentech, Inc.

在研机构

Celgene Corp.

The University of Texas MD Anderson Cancer Center

Genmab A/S

+ [40]

非在研机构

Biogen, Inc.

University of Nebraska

University of Washington

+ [42]

权益机构

上海罗氏制药有限公司

青岛百洋医药股份有限公司

Biogen, Inc.

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (1997-11-26),

非霍奇金淋巴瘤

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (日本)

登录后查看时间轴

结构/序列

Sequence Code 27145L

来源: *****

Sequence Code 83181H

来源: *****

关联

2,599

项与利妥昔单抗相关的临床试验

NCT06015750

/ Not yet recruiting临床4期

An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)

The primary objective of this study is to evaluate the effect of immunosuppressive therapy (IST) in participants treated with asfotase alfa who demonstrate immune-mediated loss of effectiveness (LoE).

开始日期2026-07-29

申办/合作机构

Alexion Pharmaceuticals, Inc.

NCT07137481

/ Not yet recruiting临床2期IIT

Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies

To determine the safety and efficacy (1-year PFS) of iC9/CD5CAR/IL-15 NK cells as consolidation in patients with aggressive T-cell malignances in first remission.

开始日期2026-02-28

申办/合作机构

The University of Texas MD Anderson Cancer Center

NCT07097363

/ Not yet recruiting临床2期IIT

A Pilot Study of Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas

This phase II trial tests the safety, best dose, and effectiveness of epcoritamab when given with etoposide, cyclophosphamide, vincristine, doxorubicin, prednisone and rituximab (EPOCH-R) for the treatment of patients with aggressive B-cell non-Hodgkin lymphoma. Epcoritamab is a bispecific antibody that can bind to two different antigens at the same time. Epcoritamab binds to CD3, a T-cell surface antigen, and CD20 (a tumor-associated antigen that is expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell cancers) and may interfere with the ability of cancer cells to grow and spread. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. The EPOCH-R is administrated as the standard of care treatment. This may help the immune system kill cancer cells. Giving epcoritamab with EPOCH-R may be safe, tolerable, and effective in treating patients with aggressive B-cell non-Hodgkin lymphoma.

开始日期2026-01-01

申办/合作机构

University of Washington

[+1]

100 项与利妥昔单抗相关的临床结果

登录后查看更多信息

100 项与利妥昔单抗相关的转化医学

登录后查看更多信息

100 项与利妥昔单抗相关的专利（医药）

登录后查看更多信息

11,127

项与利妥昔单抗相关的文献（医药）

2025-12-31·RENAL FAILURE

The efficacy and safety of rituximab monotherapy in the new onset pediatric idiopathic nephrotic syndrome: a randomized controlled clinical trial

Article

作者: He, Si-Yi ; Zhao, Jing-Li ; Dou, Ya-Lan ; Wang, Jing-Jing ; Shen, Hui-Jun ; Liu, Fei ; Zhang, Xiao-Jing ; Fu, Hai-Dong ; Li, Qiu-Yu ; Huang, Ling-Fei ; Lu, Zhi-Hong ; Sheng, Ai-Qin ; Yan, Wei-Li ; Mao, Jian-Hua ; Feng, Chun-Yue

BACKGROUND:

Nephrotic syndrome (NS) is a common form of glomerular disease in children, characterized by a high propensity for relapse. Prolonged use of glucocorticoids (GCs) can result in various side effects. Rituximab (RTX) may be considered as an initial treatment option for primary nephrotic syndrome in pediatric patients.

METHODS:

We conducted a prospective, single-center, randomized controlled trial (RCT) to evaluate whether the initial use of RTX monotherapy is superior to GC therapy in treating pediatric idiopathic NS and to assess its safety. The primary outcome and secondary outcomes were compared between the two groups.

RESULTS:

A total of 24 pediatric patients were included in the study, comprising 19 males and 5 females. After six weeks of treatment, the complete remission (CR) rate in the GC group was significantly higher than that in the RTX group (100% vs 33.3%). Compared with the RTX group, the GC group had a shorter time to first remission (14.25 d vs. 9.5 d). During the follow-up period, none of the patients in the RTX group who achieved CR experienced relapse, with the longest relapse-free duration being 79 weeks. In the GC group, nine patients experienced relapse with the longest relapse-free period being 94 weeks. No serious adverse events occurred in either group. The cumulative steroid dosage was not statistically different between the 2 groups (p = 0.41).

CONCLUSION:

Although the CR rate of children with idiopathic NS treated with RTX alone is significantly lower, the relapse rate among responders to RTX is also lower than that of the GC treatment.

2025-12-31·RENAL FAILURE

Management of rituximab in patients with PLA2R-associated membranous nephropathy of different age: a single-center retrospective cohort study

Article

作者: Song, Lei ; Ke, Ben ; Wang, Le ; Shen, Wen ; Li, Xueting

BACKGROUND:

Rituximab (RTX) has become the first-line therapy for idiopathic membranous nephropathy (IMN). The safety of low-dose and long-course RTX regimen in elderly patients with IMN remains unknown.

METHODS:

Sixty-nine IMN patients with anti-M-phospholipase A2 receptor (PLA2R) antibodies-positive were recruited for this study. The patients were categorized into two groups based on their age. The different age groups were further divided into the recommended RTX group and the low-dose and long-course RTX group. Compare the outcomes and adverse events of patients between different groups after 9-month follow-up.

RESULTS:

There was no significant difference in the complete remission rate and composite remission rate in patients with IMN in different age who received different RTX regimens. As expected, the risk of adverse events was higher in the recommended-dose RTX group compared with the low-dose and long-course RTX group in patients with IMN aged ≥60 years (66.7% vs. 19%, p = .006), and the main adverse event was infection (p = .019). Moreover, we found that different regimens were independent risk factor for infection in patients with IMN aged ≥60 years. Furtherly, ROC curve analysis suggest that in the first month after RTX used, compared with the percentage of CD19⁺ B lymphocytes, the percentage of eosinophilic granulocytes was more sensitive in predicting the risk of infection in elderly IMN patients (AUC = 0.329 vs. AUC = 0.555).

CONCLUSIONS:

The low-dose and long-course RTX regimen should be recommended for elderly patients with IMN, and the percentage of eosinophilic granulocytes is a better risk predictor of infections after RTX used in elderly patients with IMN.

2025-12-31·Hematology

Dose adjusted EPOCH-R is superior to RCHOP in frontline treatment of mediastinal large B cell lymphoma

Article

作者: Shahin, Omar ; Al-Rwashdeh, Mohammad ; Abufara, Alaa ; Muqbel, Ro’a ; Halahleh, Khalid ; Al-rabi, Kamal ; Al-Ibraheem, Akram ; Abed, Nebras Abu ; Farfoura, Heba ; Abdel-Razeq, Hikmat ; Ma'koseh, Mohammad ; Yaseen, Abeer ; Rahman, Zaid Abdel

INTRODUCTION:

Primary Mediastinal Large B Cell Lymphoma (PMLBCL) is a rare but aggressive B-cell lymphoma. This study compares the outcomes and toxicities of DA-EPOCH-R (Dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin in combination with rituximab) and RCHOP-21 (rituximab, cyclophosphamide, doxorubicin, and vincristine, every 21 days) in the treatment of newly diagnosed PMLBCL.

METHODS:

We retrospectively reviewed the medical records of adults (>18 years) diagnosed with PMLBCL and treated at our center from 2010 to 2023. Baseline characteristics were compared using chi-square and Mann Whitney U-tests. Survival outcomes were analysed using Kaplan Meier and log-rank tests.

RESULTS:

Eighty-seven patients were included, with a median age of 30 years (range: 18-55), 48 patients (55.2%) received RCHOP-21, and 39 patients (44.8%) received DA-EPOCH-R. Radiotherapy was more frequent in the RCHOP-21 group (66.6% vs 15%, p < 0.001). DA-EPOCH-R achieved a higher complete metabolic response (CMR) (92% vs 69%, p = 0.007). After a median follow-up of 47.4 months, patients treated with DA-EPOCH-R had superior overall survival (OS) and progression free survival (PFS); 3-year OS rates were 94.4% vs 69.8% (p = 0.01) and the 3-year PFS rates were 86.7% vs 62.2% (p = 0.016), particularly in patients with aa-IPI >1. Post-chemotherapy delta SUV max <0.75, and <0.7 correlated with relapse and mortality, respectively. Grade III-IV anemia and non-hematological toxicities were more frequent in the DA-EPOCH-R, but no therapy-related deaths occurred.

CONCLUSIONS:

DA-EPOCH-R improves CMR, PFS, and OS compared to R-CHOP-21 with radiotherapy in PMLBCL, particularly in high-risk patients. Longer follow-up is needed to assess long-term toxicities.

2,117

项与利妥昔单抗相关的新闻（医药）

2025-09-23

·医药经济报

恒瑞、科伦1类新药申报上市，艾伯维双抗新适应症国内报产

针对不孕不育，恒瑞 1 类小分子新药申报上市 9 月 23 日，CDE 官网显示，恒瑞医药 SHR7280 片上市申请获受理。根据临床试验进展，有媒体推测其用于辅助生殖。（来源：CDE官网，下同） SHR7280 是恒瑞自主开发的一款口服促性腺激素释放激素（GnRH）拮抗剂，通过阻断内源性 GnRH 与受体的结合，抑制促性腺激素的合成与释放，在控制性超速排卵（COH）过程中能够有效抑制早发黄体生成素（LH）峰，与注射制剂相比能够避免注射疼痛。科伦博泰A400/EP0031上市获受理 9 月 23日，科伦博泰宣布1 类新药富马酸仑博替尼胶囊（A400/EP0031）上市申请获受理。根据公开信息和临床试验进展，用于治疗RET融合阳性局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。本次受理是基于KL400-I/Ⅱ-01研究中两个关键2期队列治疗1L和2L及以上RET融合阳性NSCLC的积极结果。 KL400-I/Ⅱ-01研究中2期阶段包含队列1和队列2，分别评估A400/EP0031每天一次（QD） 90mg口服治疗经治和初治的RET融合阳性局部晚期或转移性NSCLC患者的有效性和安全性。两个关键临床研究队列的主要有效性终点已达到，A400/EP0031在经治和初治的NSCLC患者中（包括既往经免疫疗法治疗或脑转移患者）展示出良好的疗效。A400/EP0031亦显示出令人鼓舞的、可管理的耐受性和安全性。仑博替尼（A400/EP0031）是科伦博泰自主研发的第二代小分子选择性 RET 抑制剂 (SRI），对常见的 RET 基因融合和突变具有广泛活性。因此，仑博替尼具有克服第一代 SRI 耐药的潜力。艾伯维艾可瑞妥单抗又一项适应症在国内申报上市 9月23日，据CDE官网最新公示：艾伯维旗下双特异性抗体药物「艾可瑞妥单抗注射液」新适应症申报上市，拟联合利妥昔单抗和来那度胺适用于治疗复发或难治性滤泡性淋巴瘤（FL）成人患者。该适应症此前已被CDE纳入优先审评，审评进程有望加速。艾可瑞妥单抗（Epcoritamab）是一款 CD20×CD3 双抗，最初由 Genmab 公司开发。 2020 年，艾伯维与 Genmab 达成一项总额达 39 亿美元的合作，以共同开发和商业化 Genmab 的三种下一代双抗产品，其中就包括 Epcoritamab。作为一款 IgG1 双特异性抗体，艾可瑞妥单抗可同时与 T 细胞上的 CD3 和 B 细胞上的 CD20 结合，并诱发 T 细胞介导的淋巴瘤 B 细胞杀伤。艾可瑞妥单抗于 2023 年 5 月全球首批。截至目前，该药已在美国、欧盟、日本获批上市，获批适应症涵盖弥漫性大 B 细胞淋巴瘤、滤泡性淋巴瘤、原发纵隔大 B 细胞淋巴瘤。2024 年，艾可瑞妥单抗的全球销售额为 2.81 亿美元。编辑：陈丽娜版式编辑：陈淑文审校：马飞、张松上半年医药物流费超500亿，国控、华润、上药、九州通份额近半 CSCO年会回顾：抗癌创新热浪涌动，全球同步研发的挑战与破局定点药店退保潮涌！医保监管升级：倒查1-2年费用 www.yyjjb.com.cn 洞悉行业趋势长按关注医药经济报《中国处方药》学术公众号聚焦药学学术和循证研究长按关注中国处方药《医药经济报》终端公众号记录药品终端产经大事件长按关注21世纪药店

优先审批申请上市上市批准

2025-09-23

·药时空

又一项适应症！艾伯维重磅CD20×CD3双抗国内申报上市

2025年9月23日，据国家药品监督管理局药品审评中心（CDE）显示，艾伯维的艾可瑞妥单抗注射液上市申请获受理，受理号为JXSS2500127和JXSS2500128。8月，艾可瑞妥单抗注液拟纳入优先审评，适应症为联合利妥昔单抗和来那度胺适用于治疗复发或难治性滤泡性淋巴瘤（FL）成人患者，故推测此次申报的适应症可能有此。图1：艾伯维的艾可瑞妥单抗注射液上市申请获受理（来源：CDE）艾可瑞妥单抗（Epcoritamab）是一款CD20×CD3双抗，可同时与T细胞上的CD3和B细胞上的CD20结合，并诱发T细胞介导的淋巴瘤B细胞杀伤。该药物最初由Genmab公司利用DuoBody技术平台开发。2020年6月，艾伯维与Genmab达成39亿美元合作协议，联合开发包括Epcoritamab在内的三种下一代双抗产品，双方共同负责日本和美国的商业化责任，而艾伯维负责进一步的全球化开发。图2：艾可瑞妥单抗的作用机制（来源：艾伯维官网） 2023年5月，FDA批准艾可瑞妥单抗上市。目前，该药物已在美国、欧盟、日本获批上市，适应症涵盖弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤、原发纵隔大B细胞淋巴瘤。今年5月初，Genmab向FDA递交新适应症的上市申请，用于联合来那度胺+利妥昔单抗（商品名：美罗华）治疗至少一种全身治疗的复发性/难治性滤泡性淋巴瘤（R/R FL），并获优先审评，PDUAC时间2025年11月30日。 8月7日，Genmab在其官网宣布了III期EPCORE®FL-1试验的积极结果，该试验旨在评估皮下注射双特异性抗体Epcoritamab联合利妥昔单抗和来那度胺（R2）治疗复发或难治性（R/R）滤泡性淋巴瘤（FL）成年患者的疗效。结果显示，Epcoritamab联合利妥昔单抗和来那度胺（R2）治疗复发/难治性滤泡性淋巴瘤（FL）患者，与单独使用R2方案相比，其总缓解率（ORR：95.7%，p<0.0001）和无进展生存期（HR 0.21，p值<0.0001）均显著改善。在市场表现方面，2024年，艾可瑞妥单抗全球销售额达2.81亿美元，成为艾伯维在血液肿瘤领域的核心增长产品之一。今年上半年收入1.21亿美元，同比去年同期增长92.1%。在中国，艾伯维已于2024年11月向CDE递交了两项艾可瑞妥单抗的上市申请并获受理（受理号：JXSS2400101、2400100），今日又有两项上市申请获得受理，所覆盖的适应症数量刚好与全球已获批或正在申报的适应症数量相当了。据了解，全球范围内现共有4款CD20×CD3双抗获批，除了艾伯维/Genmab的艾可瑞妥单抗外，其他三款产品分别为罗氏/渤健的莫妥珠单抗、罗氏的格罗菲妥单抗、再生元/再鼎医药的奥德罗奈昔单抗。在国内，目前仅有莫妥珠单抗和格罗菲妥单抗获批上市。表1：全球CD20×CD3双抗赛道管线（来源：凯莱英药闻）参考资料： [1] ORR 达 95.7%！艾伯维重磅双抗拟纳入优先审评. 丁香园 Insight 数据库. 2025-08-21. [2] 艾伯维CD3/CD20双抗国内拟纳入优先审评. 药渡Daily. 2025-08-21. [3] 艾伯维重磅双抗拟纳入优先审评，CD20/CD3赛道迎新突破. 凯莱英药闻. 2025-08-21. 识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

优先审批临床3期上市批准申请上市

2025-09-23

·丁香园 Insight 数据库

ORR 达 95.7%！艾伯维重磅双抗又一项适应症在国内报上市

9 月 23 日，CDE 官网显示，艾伯维的艾可瑞妥单抗注液新适应症申报上市，联合利妥昔单抗和来那度胺适用于治疗复发或难治性滤泡性淋巴瘤（FL）成人患者，此前该适应症获 CDE 纳入优先审评。截图来自：CDE 官网艾可瑞妥单抗（Epcoritamab）是一款 CD20×CD3 双抗，最初由 Genmab 公司开发。 2020 年，艾伯维与 Genmab 达成一项总额达 39 亿美元的合作，以共同开发和商业化 Genmab 的三种下一代双抗产品，其中就包括 Epcoritamab。作为一款 IgG1 双特异性抗体，艾可瑞妥单抗可同时与 T 细胞上的 CD3 和 B 细胞上的 CD20 结合，并诱发 T 细胞介导的淋巴瘤 B 细胞杀伤。艾可瑞妥单抗于 2023 年 5 月全球首批。截至目前，该药已在美国、欧盟、日本获批上市，获批适应症涵盖弥漫性大 B 细胞淋巴瘤、滤泡性淋巴瘤、原发纵隔大 B 细胞淋巴瘤。2024 年，艾可瑞妥单抗的全球销售额为 2.81 亿美元。艾可瑞妥单抗关键研究进展时光轴截图来自：Insight 数据库在国内，艾伯维在 24 年 11 月递交了艾可瑞妥单抗注射用浓溶液的首个上市申请，推测适应症为复发/难治性弥漫性大 B 细胞淋巴瘤。本次上市申请针对的适应症为艾可瑞妥单抗联合利妥昔单抗和来那度胺适用于治疗复发或难治性滤泡性淋巴瘤。在关键 Ⅲ 期研究 EPCORE FL-1（NCT05409066）试验中，研究人员评估了艾可瑞妥单抗+利妥昔单抗+来那度胺治疗复发/难治性滤泡性淋巴瘤患者的安全性和有效性，对照组为利妥昔单抗+来那度胺。试验的双重主要终点是 ORR 和 PFS。该试验的首次中期分析数据显示，ORR 为 95.7%（p 值< 0.0001），PFS（HR 0.21，p 值< 0.0001）也具有显著统计学意义。基于这一结果，美国 FDA 已在今年 7 月 24 日受理艾可瑞妥单抗+利妥昔单抗+来那度胺治疗复发/难治性滤泡性淋巴瘤的上市申请，并授予其优先审评，PDUFA 日期为 2025 年 11 月 30 日。 2025 年 8 月 7 日，Genmab 宣布 EPCORE FL-1 临床试验取达到了 ORR 和 PFS 两个主要终点。艾可瑞妥单抗组在两个终点上均显示出具有统计学意义和临床意义的差异，将疾病进展或死亡风险降低了 79%。研究的具体数据将于第 67 届美国血液学会（ASH）年会上展示。 Insight 数据库显示，全球范围内现共有 4 款 CD20×CD3 双抗获批，分别为罗氏/渤健的莫妥珠单抗、罗氏的格罗菲妥单抗、艾伯维/Genmab 的艾可瑞妥单抗、再生元/再鼎医药的奥德罗奈昔单抗。在国内，目前仅有格罗菲妥单抗、莫妥珠单抗获批上市。 CD20×CD3 双抗研究进度概览图截图来自：Insight 数据库封面来源：企业 logo 免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。编辑：馨药 PR 稿对接：微信 insightxb 投稿：微信 insightxb；邮箱 insight@dxy.cn

优先审批申请上市引进/卖出临床2期上市批准

100 项与利妥昔单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02994	利妥昔单抗	L01XC02	DB00073

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
心脏移植排斥反应	日本	Zenyaku Kogyo Co., Ltd.	2023-12-22
肝移植排斥反应	日本	Zenyaku Kogyo Co., Ltd.	2023-12-22
肺移植排斥反应	日本	Zenyaku Kogyo Co., Ltd.	2023-12-22
胰腺移植排斥反应	日本	Zenyaku Kogyo Co., Ltd.	2023-12-22
肾移植排斥反应	日本	Zenyaku Kogyo Co., Ltd.	2023-12-22
小肠移植排斥	日本	Zenyaku Kogyo Co., Ltd.	2023-12-22
狼疮性肾炎	日本	Zenyaku Kogyo Co., Ltd.	2023-08-23
视神经脊髓炎	日本	Zenyaku Kogyo Co., Ltd.	2022-06-20
巴西天疱疮	日本	Zenyaku Kogyo Co., Ltd.	2021-12-24
家族性寻常型天疱疮	日本	Zenyaku Kogyo Co., Ltd.	2021-12-24
获得性血栓性血小板减少性紫癜	日本	Zenyaku Kogyo Co., Ltd.	2020-02-21
CD20阳性B细胞慢性淋巴细胞白血病	日本	Zenyaku Kogyo Co., Ltd.	2019-03-26
淋巴细胞白血病	日本	IDEC Pharmaceuticals Corp.	2019-03-26
淋巴细胞白血病	日本	Genentech, Inc.	2019-03-26
慢性特发性血小板减少性紫癜	日本	Zenyaku Kogyo Co., Ltd.	2017-06-26
血小板减少性紫癜	日本	IDEC Pharmaceuticals Corp.	2017-06-26
血小板减少性紫癜	日本	Genentech, Inc.	2017-06-26
肾病综合征	日本	Genentech, Inc.	2014-08-29
肾病综合征	日本	Zenyaku Kogyo Co., Ltd.	2014-08-29
肾病综合征	日本	IDEC Pharmaceuticals Corp.	2014-08-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性 3a 级滤泡性淋巴瘤	临床3期	美国	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	中国	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	日本	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	澳大利亚	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	比利时	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	保加利亚	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	加拿大	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	克罗地亚	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	捷克	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	丹麦	Genmab A/S	2024-02-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04585893 (LCCC 1950, CTgov)	临床2期	多中心Castleman病	15	etoposide+rituximab (High-risk Patients)	範觸鹹願觸廠壓獵遞構 = 夢糧鑰衊繭窪餘願膚鏇願簾齋壓衊積鏇顧鬱顧 (廠壓積蓋構鏇鏇夢艱醖, 積鹽衊齋簾製鹹築廠獵 ~ 積鏇構獵艱憲範範壓鹹) 更多	-	2025-09-11
				rituximab (Low-risk Patients)	範觸鹹願觸廠壓獵遞構 = 構襯鬱網艱顧窪鏇壓糧願簾齋壓衊積鏇顧鬱顧 (廠壓積蓋構鏇鏇夢艱醖, 糧衊鹹餘構鑰醖窪積襯 ~ 獵齋鹽製艱窪淵製齋醖) 更多
NCT02807103 (Pubmed \| Ann Intern Med)	临床3期	Churg-Strauss综合征	105	Glucocorticoids plus rituximab	蓋襯憲遞蓋夢淵鏇糧蓋(獵蓋窪衊襯蓋鑰製鏇蓋): RR = 1.05 (95.0% CI, 0.78 ~ 1.42), P-Value = 0.75 更多	不佳	2025-09-01
				Glucocorticoids alone or in combination with cyclophosphamide in severe forms
NCT00278408 (UNFOLDER, CTgov)	临床3期	CD20阳性B细胞淋巴瘤	700	R-CHOP-21 (Interventional: 6 R-CHOP-21 for Patients With Radiotherapy Indication)	簾觸製鏇醖鏇廠齋蓋廠 = 壓鹹齋顧淵鹽鹽淵廠選艱艱艱獵廠齋衊範壓廠 (簾鑰獵齋糧窪鬱繭鑰鏇, 鑰顧遞築醖壓積鹹夢鬱 ~ 夢積鬱獵築憲鏇淵餘願) 更多	-	2025-08-26
				R-CHOP-14 (Interventional: 6 R-CHOP-14 for Patients With Radiotherapy Indication)	簾觸製鏇醖鏇廠齋蓋廠 = 簾憲築鑰鏇襯夢糧醖廠艱艱艱獵廠齋衊範壓廠 (簾鑰獵齋糧窪鬱繭鑰鏇, 壓簾醖齋餘遞鹽醖網鏇 ~ 憲膚壓築衊餘構淵壓網) 更多
NCT00923013 (CTgov)	临床2期	毛细胞白血病	175	Cladribine+Rituximab (Cohort 1 Arm 1 SubGroup 1 -Cladribine + Rituximab)	築繭獵鏇鏇觸窪獵鹹顧 = 齋膚鑰淵繭壓網鹹網積繭鬱觸鬱蓋窪廠鏇製衊 (鏇蓋顧鏇鏇鏇觸糧鑰衊, 壓鏇廠窪網積鹹餘獵繭 ~ 淵觸顧簾齋襯獵襯網鏇) 更多	-	2025-08-08
				Cladribine+Rituximab (Cohort 1 Arm 1 SubGroup 2 -Cladribine + Rituximab)	築繭獵鏇鏇觸窪獵鹹顧 = 鑰簾觸鬱鹽顧鑰鹽醖製繭鬱觸鬱蓋窪廠鏇製衊 (鏇蓋顧鏇鏇鏇觸糧鑰衊, 蓋簾觸艱築憲壓簾淵壓 ~ 窪範糧獵夢範鑰鬱願糧) 更多
NCT02911142 (CTgov)	临床1/2期	原发性渗出性淋巴瘤	17	Lenalidomide+EPOCH+etoposide+cyclophosphamide+etoposide phosphate+prednisone+doxorubicin+Vincristine+rituximab (DA-EPOCH-R) (All Participants)	醖蓋網鹽繭夢構齋製範 = 廠獵衊構鏇夢艱製簾製齋餘膚觸築簾醖鹹餘衊 (襯醖廠餘廠鏇壓窪醖願, 膚蓋鑰選獵餘醖憲網選 ~ 顧蓋願鏇範淵願憲淵廠) 更多	-	2025-07-28
				Lenalidomide+Cyclophosphamide+Etoposide Phosphate+Prednisone+Doxorubicin+Rituximab+Vincristine (Lenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab)	廠膚糧襯鬱襯齋餘廠網(構範遞衊鏇選艱糧願齋) = 鑰蓋鬱築艱膚網餘齋蓋壓鏇觸餘齋齋鏇鬱鏇衊 (餘獵鑰鹹簾鬱鑰選積製, 膚繭選網齋淵築齋選齋 ~ 鏇觸蓋壓築衊獵鬱蓋觸) 更多
NCT00878254 (CTgov)	临床2期	套细胞淋巴瘤	25	Mesna+Etoposide+Cyclophosphamide+Leucovorin+G-CSF+Doxorubicin+ifosfamide+Methotrexate+Rituximab+Vincristine+Cytarabine	遞衊夢顧獵淵醖觸醖網(選糧廠製選夢遞廠積鹹) = 顧壓襯觸鬱廠顧築糧醖築製壓夢鏇遞壓鹽鹹壓 (觸衊淵醖範壓鹹艱衊鑰, 鹹齋鹹簾壓鬱鹽鑰衊積 ~ 鑰壓願憲憲簾蓋鏇遞鏇) 更多	-	2025-07-23
NCT00001379 (CTgov)	临床2期	淋巴瘤样肉芽肿病	94	interferon+etoposide+cyclophosphamide+prednisone+doxorubicin+vincristine+rituximab (EPOCH-R) (Participants Treated With Initial Interferon Therapy)	網鹽鏇憲選築積鏇齋鑰 = 獵齋觸襯獵淵繭淵廠範鏇鹽蓋餘鏇壓淵壓簾繭 (糧簾範齋築選築齋網夢, 繭廠窪製憲廠繭簾壓鹽 ~ 遞糧範廠觸簾糧餘艱築) 更多	-	2025-06-19
				Etoposide+Cyclophosphamide+Prednisone+Doxorubicin+Rituximab+Vincristine (Treated With Initial Etoposide,Prednisone,Vincristine,Cyclophosphamide,Doxorubicin,Rituximab Therapy)	網鹽鏇憲選築積鏇齋鑰 = 糧築蓋願壓夢範衊鏇選鏇鹽蓋餘鏇壓淵壓簾繭 (糧簾範齋築選築齋網夢, 糧衊獵鹽鏇膚繭鏇鹹襯 ~ 衊遞獵鬱鹹鹽築簾壓壓) 更多
NCT05168475 (BIOVAS, CTgov)	临床2期	过敏性紫癜 \| 原发性中枢神经系统血管炎 \| 大动脉炎 ... 更多	22	Tocilizumab+Rituximab (Infliximab)	製獵觸壓鏇窪顧糧壓鹹 = 衊繭簾網繭鏇憲構遞觸淵醖鬱遞鏇觸鬱繭糧獵 (選醖醖選鏇憲夢齋餘衊, 壓鬱艱醖製淵構範願鬱 ~ 淵觸願簾窪簾鬱顧蓋願) 更多	-	2025-06-17
				Infliximab+Tocilizumab (Rituximab)	製獵觸壓鏇窪顧糧壓鹹 = 壓淵製鑰齋夢範襯糧顧淵醖鬱遞鏇觸鬱繭糧獵 (選醖醖選鏇憲夢齋餘衊, 衊鬱製製築簾鏇壓鑰廠 ~ 艱壓遞夢鬱壓顧廠築顧) 更多
NCT04182204 (POLARGO, EHA2025) 人工标引	临床3期	难治性弥漫性大 B 细胞淋巴瘤	255	Pola-R-GemOx	壓範鹽餘觸願膚鬱衊艱(齋餘選淵鹹餘觸襯醖鬱) = 鹽築遞窪窪齋壓膚積顧鬱夢積構蓋繭鏇衊廠顧 (膚鹽簾蓋窪簾簾窪鑰鑰, 13.3 ~ NE) 更多	积极	2025-06-13
				R-GemOx	壓範鹽餘觸願膚鬱衊艱(齋餘選淵鹹餘觸襯醖鬱) = 遞簾艱齋範憲積鬱襯窪鬱夢積構蓋繭鏇衊廠顧 (膚鹽簾蓋窪簾簾窪鑰鑰, 8.9 ~ 15.8) 更多
EULAR2025	N/A	类风湿关节炎一线	170	Rituximab	夢選膚夢窪鑰鏇觸壓範(範遞鬱糧選築膚鏇構憲) = 艱憲鹹夢願壓製齋壓觸範築蓋積醖醖簾構繭構 (範構醖願醖範艱廠構選 ) 更多	积极	2025-06-11